Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia

References

• De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003; 24: 1601–10
   PubMed Web of Science ®Google Scholar
• Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44: 720–32
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists' Collaborators (CTT). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267–78
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis. 2007; 194: 1–45
   PubMed Web of Science ®Google Scholar
• Euroaspire II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from Euroaspire II Euro Heart Survey Programme Eur Heart J. 2001;22:554–72.
   PubMed Web of Science ®Google Scholar
• Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in population cholesterol levels 1986–2004: Influence of lipid-lowering drugs, obesity, smoking and educational level. The Northern Sweden MONICA study. J Int Med. 2006; 260: 551–9
   PubMed Web of Science ®Google Scholar
• Kristensen JK, Lauritzen T. Inadequate treatment of dyslipidemia in people with type 2 diabetes: Quality assessment of diabetes care in a Danish County. Scand J Prim Health Care. 2006; 24: 181–5
   PubMed Web of Science ®Google Scholar
• Alemao E, Yin D, Sintonen H, Salomaa V, Jousilathi P. Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: The National FINRISK Study. Am J Cardiovasc Drugs. 2006; 6: 349–55
   PubMedGoogle Scholar
• Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao E, Yin DD, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs. 2006; 6: 121–8
   PubMedGoogle Scholar
• Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML. Risk assessment and treatment of dyslipidemia in primary health care. Dan Med Bull. 2005; 52: 82–5
   PubMed Web of Science ®Google Scholar
• Lindgren P, Borgström F, Stålhammer J, Alemao E, Yin DD, Jönsson L. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinic practice. Eur J Cardiovasc Prev Rehabil. 2005; 12: 530–4
   PubMed Web of Science ®Google Scholar
• Eliasson B, Cederholm J, Nilsson P, Gudbjörnsdóttir S. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996–2003. Diabet Med. 2005; 22: 1420–6
   PubMed Web of Science ®Google Scholar
• Kanstrup H, Lassen JF, Heickendorff L, Lauritzen T, Larsen ML. Quality of lipid-lowering therapy in patients with ischaemic heart disease: A register-based study in 3477 patients. J Int Med. 2004; 255: 267–72
   Google Scholar
• Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: The Oslo Health Study 2000–2001. J Int Med. 2004; 255: 494–502
   PubMed Web of Science ®Google Scholar
• Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njølstad I. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: The Tromsø study 2001. Eur J Clin Pharmacol. 2004; 60: 643–9
   PubMed Web of Science ®Google Scholar
• Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, et al. An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study. Clin Ther. 2003; 25: 1186–99
   PubMed Web of Science ®Google Scholar
• Kahan T, Wändell P. Risk factors in established coronary heart disease: Evaluation of a secondary prevention programme. J Cardiovasc Risk. 2001; 8: 73–80
   PubMedGoogle Scholar
• Strandberg T, Vanhanen H., Lääkityksen. Impact of medication and the characteristics of patients and physicians on the achievement of lipid treatment goals. Suomen Lääkärilehti. 2001; 56: 1483–6
   Google Scholar
• Strandberg T, Vanhanen H. Reaching the goals for the treatment of dyslipidemia between 2000 and 2005. Has there been any progress?. Suomen Lääkärilehti. 2000; 61: 4689–94
   Google Scholar
• Notø ATW, Steffensen L, Nordøy A, Hansen J-B. Use of statins in hospital after acute myocardial infarction. Tidsskr Nor Lægeforen. 2001; 121: 2467–71
   PubMedGoogle Scholar
• Kanstrup H, Lassen JF, Heickendorff L, Larsen ML. Treatment and monitoring of dyslipidaemia in patients discharged after acute myocardial infarction. Ugeskr Læger. 2001; 163: 6593–7
   PubMedGoogle Scholar
• Svilaas A, Risberg K, Thoresen M, Ose L. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. Am J Cardiol. 2000; 86: 1250–3
   PubMed Web of Science ®Google Scholar
• Svilaas A, Thoresen M, Kristoffersen JE, Hjartaaker J, Westheim A. How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. Scand J Prim Health Care. 2000; 18: 232–6
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Vanhanen H. Long standing heart disease should be better screened. BMJ. 2000; 321: 1083–4
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. The effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol. 2007; 50: 409–18
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004; 364: 771–7
   PubMed Web of Science ®Google Scholar
• LaRosa JC. Poor compliance: The hidden risk factor. Curr Atheroscler Rep. 2000; 2: 1–4
   PubMedGoogle Scholar
• Leiter LA, Betteridge DJ, Chacra AR, Chait A, Ferrannini E, Haffner SM, et al. on behalf of the AUDIT study steering committee. AUDIT Study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis. 2006; 6: 31–40
   Google Scholar
• Rasmussen JN, Gislasson GH, Abildstrøm SZ, Rasmussen S, Gustafsson I, Buch J, et al. Statin use after acute myocardial infarction: A nationwide study in Denmark. Br J Clin Pharmacol. 2005; 60: 150–8
   PubMed Web of Science ®Google Scholar
• Melberg T, Thoresen M, Hansen JB, Westheim A. How are patients with acute coronary syndrome treated in Norwegian hospitals?. Tidskr Nor Lægeforen. 2005; 125: 2925–8
   PubMedGoogle Scholar
• Kvan I, Pettersen KI, Landmark K, Reikvam Å. INPHARM study investigators. Treatment with statins after acute myocardial infarction in patients (80 years: Underuse dispute general acceptance of drug therapy for secondary prevention. Pharmacoepidemiol Drug Saf. 2006; 15: 261–7
   PubMed Web of Science ®Google Scholar
• Roberts CGP, Guallar E, Rodriquez A. Efficacy and safety of statin monotherapy in older adults: A meta-analysis. J Gerontol Medical Sciences. 2007; 62A: 879–87
   Google Scholar
• Poussa H, Strandberg TE, Tikkanen I, Kauhanen P, Lepäntalo M. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Scand Cardiovasc J. 2007; 41: 138–41
   PubMed Web of Science ®Google Scholar
• Christensen B, Duedal P. Post-graduate training in cardiovascular disease. General Practitioners become more competent to help coronary patients when they simultaneously allow themselves to be educated in the topic. Månedsskr Prakt Lægegern. 2003; 81: 1215–23
   Google Scholar
• Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: A randomized controlled trial in general practice with 5-year follow-up. J Fam Pract. 2002; 51: 546–52
   PubMed Web of Science ®Google Scholar
• Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48: 438–45
   PubMed Web of Science ®Google Scholar
• Cannon CP. The IDEAL cholesterol. Lower is better. JAMA. 2005; 294: 2492–4
   PubMed Web of Science ®Google Scholar
• Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007; 297: 1344–53
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006; 22: 2041–53
   PubMed Web of Science ®Google Scholar
• Scirica BM, Cannon CP. Treatment of elevated cholesterol. Circulation. 2005; 111: 360–e3
   Google Scholar